Drug Trial Radar · NCT07169175
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Mar 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- SineuGene Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
SNUG01Drug
AAV (adeno-associated virus) Gene therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety and tolerability of SNUG01 administered by intrathecal.Time frame: up to 1 year after administration
- To recommend the optimal expansion dose of SNUG01 that demonstrates acceptable safety with maximum preliminary efficacy administered by IT.Time frame: up to 1 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Peking University Third Hospital
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.